Acute Aβ12‐28P administration targeting apoE/Aβ interaction rescues synaptic function and cognitive decline in advanced‐stage Alzheimer’s disease
Shuo Chen, Nikolas Lam, Zhiheng Li, Ding Wang, Pengfu Liu, Victoria Berbano, Yu Xie, Tyra Nguyen, Yvonne Xu, John Yang, Karen Ha, Leonardo Semana, Rachel Dias, Arjun V Masurkar, Thomas Wisniewski · 2025
Read Acute Aβ12‐28P administration targeting apoE/Aβ interaction rescues synaptic function and cognitive decline in advanced‐stage Alzheimer’s disease by Shuo Chen, Nikolas Lam, Zhiheng Li, Ding Wang, Pengfu Liu, Victoria Berbano, Yu Xie, Tyra Nguyen, Yvonne Xu, John Yang, Karen Ha, Leonardo Semana, Rachel Dias, Arjun V Masurkar, Thomas Wisniewski (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11714001.txt.
Description
Shuo Chen and co-authors test a peptide drug in old mice with Alzheimer's-like disease in a 2025 study. The peptide blocks the binding between apoE4, the top genetic risk factor for late-onset disease, and amyloid beta, the protein that forms plaques. Earlier work in middle-aged mice showed less plaque and better memory.
The new test used very old mice, 18 to 24 months, with disease well advanced. Daily doses brought quick gains in several memory and movement tests within hours of each shot. After three weeks, brain slices from treated mice showed stronger synapse responses. The result suggests late-stage brains can still respond fast to this block.
Catalog record
| CREATOR | Shuo Chen, Nikolas Lam, Zhiheng Li, Ding Wang, Pengfu Liu, Victoria Berbano, Yu Xie, Tyra Nguyen, Yvonne Xu, John Yang, Karen Ha, Leonardo Semana, Rachel Dias, Arjun V Masurkar, Thomas Wisniewski |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |